Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Innate Pharma (IPHA) has disclosed Non-Current Debt for 8 consecutive years, with $23.8 million as the latest value for Q4 2024.

• For the quarter ending Q4 2024, Non-Current Debt fell 28.5% year-over-year to $23.8 million, compared with a TTM value of $23.8 million through Dec 2024, down 28.5%, and an annual FY2024 reading of $24.1 million, down 27.97% over the prior year.
• Non-Current Debt was $23.8 million for Q4 2024 at Innate Pharma, down from $33.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $41.0 million in Q4 2022 and bottomed at $15.4 million in Q4 2021.
• Average Non-Current Debt over 5 years is $26.7 million, with a median of $23.8 million recorded in 2024.
• The sharpest move saw Non-Current Debt surged 165.18% in 2022, then fell 28.5% in 2024.
• Year by year, Non-Current Debt stood at $20.2 million in 2020, then decreased by 23.54% to $15.4 million in 2021, then soared by 165.18% to $41.0 million in 2022, then dropped by 18.69% to $33.3 million in 2023, then dropped by 28.5% to $23.8 million in 2024.
• Business Quant data shows Non-Current Debt for IPHA at $23.8 million in Q4 2024, $33.3 million in Q4 2023, and $41.0 million in Q4 2022.

Peer Comparison